<DOC>
	<DOCNO>NCT02780778</DOCNO>
	<brief_summary>The purpose Phase II , Open-label , single arm , exploratory study evaluate efficacy safety Apatinib（500mg/d）with docetaxel ( 60 mg/m² ) advance Non-squamous Non-small cell lung cancer failure first line chemotherapy .</brief_summary>
	<brief_title>Apatinib Plus Docetaxel 2nd Line Treatment Patients With Advanced Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>≥ 18 ≤ 75 year age Histologically cytologic confirm advanced nonsquamous nonsmall cell lung cancer . EGFR mutation test negative sensitive mutation At least one measurable lesion receive radiotherapy ( large 10 mm diameter spiral CT scan ) Have fail 1 line chemotherapy ECOG performance scale 0 1 . Life expectancy 3 month . Duration last therapy 6 week nitroso mitomycin More 4 week operation radiotherapy More 4 week cytotoxic agent Adequate hepatic , renal , heart , hematologic function ( hemoglobin ≥ 90g/L , platelet ≥ 80×10^9/L , neutrophil ≥ 1.5×10^9/L , total bilirubin within 1.25×the upper limit normal ( ULN ) , serum transaminase≤2.5×the ULN ( If liver metastasis , serum transaminase≤5×the ULN ) , serum creatine ≤ 1.5 x ULN , creatinine clearance rate ≥ 50ml/min , Signed date informed consent.Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Received one kind chemotherapy regimens NSCLC receive VEGFR inhibitor ( except beacizumab ) docetaxel chemotherapy Existing therapy relate toxicity prior chemotherapy and/or radiation therapy Intercurrence one following : hypertension , coronary artery disease , arrhythmia heart failure Any factor influence usage oral administration The center tumor invade local large blood vessel Within 4 week first use drug , occur pulmonary hemorrhage ( ≥ CTCAE class 2 ) part ' hemorrhage ( ≥ CTCAE class 3 ) . Within 6 month first treatment occur artery / venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism , etc . Less 4 week last clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>